Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Frontiers in Immunology|October 17, 2019
Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 CellsRonald Anderson, Annette J Theron, Bernardo L Rapoport
Melanoma Research|April 12, 2003
Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatmentDaniel A Vorobiof, Bernardo L Rapoport, Rabia Mahomed, et al.
Frontiers in Oncology|August 10, 2019
Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature ReviewRonwyn van Eeden, Bernardo L Rapoport, Teresa Smit, et al.
Current Opinion in Oncology|March 23, 2021
Supportive care for new cancer therapiesBernardo L Rapoport, Tim Cooksley, Douglas B Johnson, et al.
Pharmaceuticals (Basel, Switzerland)|November 25, 2020
Contrasting Immunopathogenic and Therapeutic Roles of Granulocyte Colony-Stimulating Factor in CancerAnnette J Theron, Helen C Steel, Bernardo L Rapoport, et al.
International Journal of Molecular Sciences|August 12, 2023
Pro-Tumorigenic and Thrombotic Activities of Platelets in Lung CancerRonald Anderson, Bernardo L Rapoport, Helen C Steel, et al.
Current Treatment Options in Oncology|December 6, 2013
When and how do I use neoadjuvant chemotherapy for breast cancer?Bernardo L Rapoport, Georgia S Demetriou, Shun D Moodley, et al.
Molecules (Basel, Switzerland)|April 5, 2020
Role of the Neutrophil in the Pathogenesis of Advanced Cancer and Impaired Responsiveness to TherapyBernardo L Rapoport, Helen C Steel, Annette J Theron, et al.
Cancer Medicine|May 24, 2018
Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapyRudolph M Navari, Bernardo L Rapoport, Dan Powers, et al.
Pageof 6